A practical reference on AOD9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-02-19. Anything still debated is marked as such rather than presented as settled.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
== Effects of supplementation on exercise == BCAAs have an insulin-like effect on glucose, lowering circulating glucose concentrations. When ingested before exercise, they can be oxidized by skeletal muscle and used as an energy source, reducing the need for the liver to increase glycogenolysis. During anaerobic exercise, pyruvate derived from glucose metabolism is converted into lactic acid. The accumulation of lactic acid can lower pH to as low as 6.4, contributing to metabolic acidosis. Elevated lactic acid levels inhibit glucose metabolism to prevent further acidification. BCAA supplementation has been reported to decrease lactic acid concentrations in muscle, thereby allowing glucose metabolism to continue during exercise. This effect reduces glycogenolysis in the liver and lowers plasma glucose during exercise, although long-term supplementation appears to have little effect on blood glucose outside of exercise. BCAAs also influence central fatigue mechanisms. They reduce circulating free fatty acids (FFA), which compete with tryptophan for binding to albumin. Lower FFA levels increase albumin-bound tryptophan, thereby decreasing free tryptophan entry into the brain. Since free tryptophan is a precursor to serotonin (5-HT), reduced tryptophan uptake lowers serotonin synthesis during exercise, diminishing the sensation of fatigue. In rats, BCAA supplementation reduced brain serotonin by up to 90%, though such reductions can also impair focus, impulse control, and executive function.
For Reynolds number greater than 4000, the flow is turbulent; the resistance to flow follows the Darcy–Weisbach equation: it is proportional to the square of the mean flow velocity. Over a domain of many orders of magnitude of Re (4000 < Re < 108), the friction factor varies less than one order of magnitude (0.006 < fD < 0.06). Within the turbulent flow regime, the nature of the flow can be further divided into a regime where the pipe wall is effectively smooth, and one where its roughness height is salient.
MR + CO2 → RCO2M where M = Li or MgBr and R = alkyl or aryl. In metal carbon dioxide complexes, CO2 serves as a ligand, which can facilitate the conversion of CO2 to other chemicals. The reduction of CO2 to CO is ordinarily a difficult and slow reaction:
Sources: en.wikipedia.org
covalent bond Also molecular bond. A bond that involves the sharing of electron pairs between atoms. The stable balance of attractive and repulsive forces that occurs between atoms when they share electrons is known as covalent bonding.
Dinosaur evolution after the Triassic followed changes in vegetation and the location of continents. In the Late Triassic and Early Jurassic, the continents were connected as the single landmass Pangaea, and there was a worldwide dinosaur fauna mostly composed of coelophysoid carnivores and early sauropodomorph herbivores. Gymnosperm plants (particularly conifers), a potential food source, radiated in the Late Triassic. Early sauropodomorphs did not have sophisticated mechanisms for processing food in the mouth, and so must have employed other means of breaking down food farther along the digestive tract. The general homogeneity of dinosaurian faunas continued into the Middle and Late Jurassic, where most localities had predators consisting of ceratosaurians, megalosauroids, and allosauroids, and herbivores consisting of stegosaurian ornithischians and large sauropods. Examples of this include the Morrison Formation of North America and Tendaguru Beds of Tanzania. Dinosaurs in China show some differences, with specialized metriacanthosaurid theropods and unusual, long-necked sauropods like Mamenchisaurus. Ankylosaurians and ornithopods were also becoming more common, but primitive sauropodomorphs had become extinct. Conifers and pteridophytes were the most common plants. Sauropods, like earlier sauropodomorphs, were not oral processors, but ornithischians were evolving various means of dealing with food in the mouth, including potential cheek-like organs to keep food in the mouth, and jaw motions to grind food.
results in a different mass. The net result is that C3 and S1H4 differ by 3.4 mDa. Even smaller differences are achievable by carefully matching isotopes. For example, C4 and S1H313C1 differ by 1.1 mDa. Such differences can be resolved by high resolution mass spectrometry, which reaches resolution >1 million, sufficient to resolve ~1 mDa difference at m/z ~ 1000. Note that the electron mass is 0.5 mDa. There are many techniques for high resolution MS, but the highest resolution is achieved by FTMS with high magnetic field. With increasing magnetic field strength, the resolution and spectral acquisition speed increases linearly, while mass accuracy and dynamic range increases quadratically. Consequently, the highest resolution is achieved by high field FTMS, up to 21 Tesla. It reaches resolution >2.7 million at m/z ~ 400, and mass measurement accuracy < 80 ppb. They are often employed in geochemical and petrochemical studies, since there is a lot of money in petroleum industry, and petroleum composition is highly complex. Another application is in isotopic analysis of large proteins. Two proteins differing by a single isotopic atom are separated by
The Shihab dynasty was an Arab family whose members served as the paramount tax farmers and local chiefs of Mount Lebanon from the early 18th to mid-19th century, during Ottoman rule. Their reign began in 1697 after the death of the last Ma'nid chief. In 1697, Amir Ahmad died without an heir, and the Druze notables chose his nephew Bashir al-Shihabi as their new ruler. He was succeeded in 1707 by the young Amir Haydar al-Shihabi, grandson of Amir Ahmad al-Ma'ni. Haydar recognized the authority of the Maronite al-Khazins and the Hubayshis of Kisrawan and Ghazir and treated these two families as equal to the feudalistic Druze families. The Shihab family realized the importance of Maronite rule and power, and they and the Maronites became united in a common interest. The family centralized control over Mount Lebanon, destroying the feudal power of the mostly Druze lords and cultivating the Maronite clergy as an alternative power base of the emirate. During Yusuf Shihab's rule, many members of the Shihab family converted to Christianity and Yusuf also began to rely on the support of the Maronite Christians. On 3 September 1840, Bashir Shihab III, a distant cousin of the once-powerful Emir Bashir Shihab II, was appointed emir of Mount Lebanon by Ottoman Sultan Abdulmejid I. Geographically, the Mount Lebanon Emirate corresponded with the central part of present-day Lebanon, which historically has had a Christian and Druze majority. In practice, the terms "Lebanon" and "Mount Lebanon" tended to be used interchangeably by historians until the formal establishment of the Mandate.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.